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Additional file 1-SPIRIT 2013 Checklist: Recommended items to address in a clinical trial 
protocol and related documents 
Section/item Item
No 
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Administrative information 
Title 1 Ketogenic diet in the treatment of epilepsy in children under the age of 
two years, KIWE  
Trial registration 2a Clinicaltrials.gov NCT02205931. Registered 16 December 2013 
Protocol version 3 27th October 2015   Version 5  
Funding 4 This project is funded by the Efficacy and Mechanism Evaluation 
(EME) Programme, an MRC and NIHR partnership (EME funding 
reference: 12/10/18).  The EME Programme is funded by the MRC 
and NIHR, with contributions from the CSO in Scotland and NISCHR 
in Wales and the HSC R&D Division, Public Health Agency in 
Northern Ireland.    
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5b Nimrita Verma (Sponsor’s Representative), Joint Research Office, 
UCL, 1st Floor Maple House, Suite A, 149 Tottenham Court Road,     
London, W1T 7DN 
Email: n.verma@ucl.ac.uk  
                                 
 5c All proposed publications will be discussed with Sponsor prior to 
publishing other than those presented at scientific forums/meetings.  
Analysis will be done on an intention-to-treat model. A full statistical 
analysis plan will be created by PRIMENT.  The sponsor will ensure 
that the trial protocol, patient information sheet, consent form, GP 
letter and submitted supporting documents have been approved by 
the appropriate regulatory body (MHRA in UK) and a main research 
ethics committee, prior to any patient recruitment. The protocol and all 
agreed substantial protocol amendments, will be documented and 
submitted for ethical and regulatory approval prior to implementation. 
Before the site can enrol patients into the trial, the Chief 
Investigator/Principal Investigator or designee must apply for NHS 
permission from their Trust Research & Development (R&D) and be 
granted written permission.  It is the responsibility of the Chief 
Investigator/ Principal Investigator or designee at each site to ensure 
that all subsequent amendments gain the necessary approval.  The 
trial is being financed by an NIHR EME programme grant for a period 
of 4 years. 
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 5d The study will be supported by the UCL PRIMENT CTU.  The Chief 
Investigator (CI) will maintain day to day responsibility for the trial 
working in close collaboration with the Clinical Trial Manager (CTM) to 
ensure that the trial is conducted, recorded and reported in 
accordance with the protocol, good clinical practice guidelines, and 
essential standard operating procedures on all aspects of trial 
management, quality control and data analyses required for running 
RCTs as documented by our Clinical Trials Unit.  All investigators will 
have up to date Good Clinical Practice training.  
 
A Trial Management Group (TMG) consisting of the CI, some of the 
co-applicants the CTM and the trial statistician will meet monthly at 
the start of the study and then quarterly on completion of recruitment.  
They will monitor the conduct and progress of the trial. The PI, CTM 
and statistician will monitor data to identify unusual patterns (Central 
Monitoring Processes).  They will also ensure that the researchers 
have access to documentation necessary for the conduct of the trial. 
 
The study will be overseen by an externally led Trials Steering Group 
(TSG) that will meet twice a year which will include two parent 
representatives recruited from Young Epilepsy. 
 
 We will also appoint a trial data monitoring committee (DMC) that will 
examine baseline data and then explore the preliminary analyses of 
study outcomes and adverse events conducted on the data at defined 
time points as determined by the Chair of the DMC.  Based on 
predefined cut off agreed by the DMC for specified outcomes the 
DMC will advise the TSG on the progress of the trials.   
 
Terms of Reference will be in place for each committee. 
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Introduction 
 
Background and 
rationale 
 
 
6a 
 
 
Epilepsy is a condition whereby individuals are prone to recurrent 
epileptic seizures, a change in behaviour or movement that is the 
direct result of a primary change in the electrical activity in the brain. It 
is not a single condition - there are many different underlying causes 
and more accurately, they should be referred to as the epilepsies.  Up 
to 65% of individuals with epilepsy will have seizures controlled with 
antiepileptic drugs (AED) or enter spontaneous remission in their 
lifetime. However, this leaves 35% who will continue with seizures 
despite treatment.  Standard first line management of an individual 
presenting with epilepsy is antiepileptic medication, decided on the 
basis of the type of epilepsy. Although guidelines exist on which drug 
to use, management is still based on a ‘trial and error’ approach. 
When the type of epilepsy or seizure is unclear, it can be difficult to 
optimise treatment at the outset. 
The incidence of epilepsy is greatest in the first two years of life (56-
88/100,000 children/year), a population who remain most at risk for 
neurodevelopmental compromise in the longer term. Early control of 
seizures is associated with better developmental outcome but, 
unfortunately, many of the epilepsies presenting in infancy are 
associated with a poor prognosis for seizure control. Little evidence is 
available with regard to effective treatments and, even where seizure 
freedom is achieved, this is unlikely to be sustained long-term. This 
group of children place a large burden on health services, with a need 
for regular clinical review and ongoing medication, as well as clinical 
and therapy support. This is especially true for those who remain 
resistant to medication, this group being amongst the most costly for 
medical and care services long-term. It is therefore imperative that all 
other treatment options are explored as early as possible.    
The ketogenic diet (KD) is a high-fat, low-carbohydrate diet designed 
to mimic the effects of starvation on the body. The main energy intake 
is fat, which is converted to ketones in the body and used as an 
energy source. The KD has been shown to be successful in 
controlling seizures in many observational studies. However, there is 
limited evidence examining efficacy against no change or alternative 
treatments from randomised controlled trials (RCTs).The first RCT of 
the KD, demonstrating effectiveness in children aged 2-16 years was 
published in 2008. In this trial, 145 children aged 2-16 years, who had 
failed at least two AEDs and had at least seven seizures weekly were 
randomized to receive a KD, either immediately or after a 3-month 
delay with no additional treatment changes (the latter being the control 
group). After three months, the mean percentage of baseline seizures 
(on an intention to treat analysis) was significantly lower in the diet 
group (62%) than in controls (137%, P <0.0001). Twenty-eight (38%) 
of the diet group had greater than 50% seizure reduction, compared to 
four (6%) controls (p<0.0001).  
The mechanism of action of the KD is not yet known. Recent evidence 
suggests that medium chain fatty acids, more specifically decanoic 
acid, may have a specific role in its antiepileptic effect. These data 
raise the possibility that C10 alone has the ability to mimic aspects of 
the KD. 
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 6b The KD is a high resource treatment, requiring patient-specific 
calculation and regular input from a specialist paediatrician and 
dietitian, with close monitoring thereafter. It also requires diligence on 
the part of the families. It is also not without side effects. It is 
imperative that the effectiveness and safety of the KD in this very 
young age group is now studied in a well-designed clinical trial. 
Objectives 7 The primary objective is to assess the effectiveness of the KD 
compared to AEDs in the treatment of infants with epilepsy aged three 
months to two years of age who continue to have seizures despite 
previous trials of two AEDs. The secondary objectives are to 
determine tolerability of the KD relative to standard AEDs, adherence 
to treatment over time, the effect on quality of life and 
neurobehavioural progress.  Further, we aim to estimate whether the 
presence of medium chain fatty acids in the context of use of the KD 
is associated with seizure control. 
Trial design 8 An open label RCT where eligible children (age three months to two 
years with epilepsy who have failed two antiepileptic drugs [AEDs]) 
undergo baseline assessment, including medical and seizure history. 
Participants then start an observation period (7 or 14 days) with 
documentation of seizure frequency. Randomisation will occur on Day 
8 or Day 15 to receive the KD or a further AED; the allocated 
treatment will commence on day 15, with instruction and training.  A 
second assessment (four weeks after start of treatment) will include 
clinical review and tolerability questionnaire (modified Hague scale of 
side effects – for those allocated to the KD group). Assessments will 
be repeated at eight weeks after the start of treatment including 
biochemical investigations, after which, according to patient response, 
KD (diet group) or AED (standard AED group) will then be continued 
or changed. Those in the AED group who have failed to achieve 
seizure control at the eight week assessment will then be offered KD 
outside the context of the trial. Those in the KD arm who fail to 
achieve seizure control will be changed to standard clinical 
management. All patients will be followed up for 12 months from 
randomisation for retention, seizure outcome, quality of life and 
neurodevelopmental status. 
Methods: Participants, interventions, and outcomes 
Study setting 9 Recruitment will be from hospital-based paediatric neurology centres, 
with the additional involvement of a user group, Matthews Friends 
Charity, an organisation set up to raise awareness and availability of 
the KD in the UK, and which now also supports clinics implementing 
the KD. Many, if not all of the suitable patients will already be under 
the care of tertiary paediatric neurology centres according to National 
Guidelines (www.nice.org.uk/cg137). 
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Eligibility criteria 10 Inclusion: Age between three months and 24 months of age (not 
beyond second birthday at baseline, diagnosis of epilepsy confirmed, 
seizure frequency greater than or equal to four seizures/ week on 
average in the baseline period, failed response to previous trial of two 
antiepileptic drugs. In the case of infantile spasms, this could include a 
trial of corticosteroid,  Children with written informed consent from 
parent/guardian and exclusion criteria for participants.  
Exclusion: Continues on corticosteroids less than two weeks prior to 
randomisation, metabolic disease contraindicating use of the KD, e.g. 
pyruvate carboxylase deficiency, medium-chain acyl-CoA 
dehydrogenase (MCAD) deficiency from previous medical 
investigation and screening at baseline, progressive neurological 
disease, severe gastroesophageal reflux, previous treatment with the 
KD, concurrent participation in another clinical trial of an 
investigational medicinal product, patients who are prescribed AEDs 
not listed in the trial IMPs, patients who have a listed contraindication 
as per the SmPC to any of the AEDs listed in the trial investigational 
medicinal products (IMPs). 
Interventions 11a An open label RCT where eligible children (age three months to two 
years with epilepsy who have failed two antiepileptic drugs [AEDs]) 
undergo baseline assessment, including medical and seizure history. 
Participants then start an observation period (7 or 14 days) with 
documentation of seizure frequency. Randomisation will occur on Day 
8 or Day 15 to receive the KD or a further AED; the allocated 
treatment will commence on day 15, with instruction and training.  A 
second assessment (four weeks after start of treatment) will include 
clinical review and tolerability questionnaire (modified Hague scale of 
side effects – for those allocated to the KD group). Assessments will 
be repeated at eight weeks after the start of treatment including 
biochemical investigations, after which, according to patient response, 
KD (diet group) or AED (standard AED group) will then be continued 
or changed. All patients will be followed up for 12 months from 
randomisation for retention, seizure outcome, quality of life and 
neurodevelopmental status. 
11b Those in the AED group who have failed to achieve seizure control at 
the eight week assessment will then be offered KD outside the context 
of the trial. Those in the KD arm who fail to achieve seizure control will 
be changed to standard clinical management. 
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11c Cross-site consistency of KD implementation will be monitored after 
the 8-week and 12-month visits by the Dietetic Assistant. Details to be 
monitored include the calculation of energy prescriptions, protein 
intake, teaching sessions, initiation regimes, supplementation and 
ketone levels.  
Treatment compliance will be captured with the use of seizure diary 
and food diary. Noncompliance to the Protocol study procedures will 
be documented by the investigator and reported to the Sponsor as 
agreed. Persistent noncompliance may lead the patient to be 
withdrawn from the study.  Efficacy of the KD and further AEDs will be 
assessed through documentation of seizure frequency by seizure 
diaries completed by parents throughout, with documentation to CRF 
at each assessment. 
 
Outcomes 12 The primary objective is to assess the effectiveness of the KD 
compared to AEDs in the treatment of infants with epilepsy aged three 
months to two years of age who continue to have seizures despite 
previous trials of two AEDs. The secondary objectives are to 
determine tolerability of the KD relative to standard AEDs, adherence 
to treatment over time, the effect on quality of life and 
neurobehavioural progress.  Further, we aim to estimate whether the 
presence of medium chain fatty acids in the context of use of the KD 
is associated with seizure control. 
Participant 
timeline 
13 The schedule of enrolment interventions and assessments (see figure 
1). 
Sample size 14 Recruitment will be expected at a rate of 28/year from GOSH, and 
approximately 7/year from the remaining seven centres (total 84/year). 
This enables a completed primary outcome in the desired 160 
children. 
Recruitment 15 An initial pilot study involving two centres over twelve months will aim 
to recruit approximately 20% of the total sample required: 35 
participants over 12 months. The pilot study will run in two centres in 
London: Great Ormond Street Hospital for Children and Evelina 
London Children’s Hospital over the initial 12 months. We will aim to 
assess approximately 50 eligible patients in this time frame. 
Additionally, Adverse Events (AEs) will be monitored and data on 
safety will be reviewed.  
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Methods: Assignment of interventions (for controlled trials) 
Allocation:   
Sequence 
generation 
16a The randomisation schedule will be independently generated and held 
by Sealed Envelope. Allocations will be released by email to the 
coordinating centres once the investigator or research nurse has 
entered eligible participant information into the web-based 
randomisation service. Participants will be allocated to either the KD 
or further AED arm using a simple, concealed, randomisation method. 
Randomisation will aim to achieve 92 in the KD group vs 68 
participants in the further AED arm.  
Allocation 
concealment 
mechanism 
16b Whilst it will not be possible to blind participants to their treatment 
allocation, efforts will be made to minimise expectation bias by 
emphasising in the trial literature that the evidence supporting the KD 
for seizure control is currently limited. 
Implementation 16c The randomisation schedule will be independently generated and held 
by Sealed Envelope and allocations released by email to the once the 
investigator or research nurse has entered eligible participant 
information into the web-based randomisation service.   
Blinding 
(masking) 
17a Not applicable 
 17b Not applicable  
 
Methods: Data collection, management, and analysis 
Data collection 
methods 
18a The investigator will ensure the accuracy of all data entered in the 
CRFs. The delegation log will identify all those personnel with 
responsibilities for data collection and handling, including those who 
have access to the trial database.  Whilst inpatient and at each 
outpatient visit, medical notes will form the source data for the trial 
and be completed as per routine practice.  
 
 18b Participants will be withdrawn from the treatment prior to 8 weeks 
should there be over 50% increase in seizure frequency from 
baseline, or if side effects e.g. diarrhoea, constipation are not resolved 
by manipulation of KD or medication.  Withdrawn patients will not be 
replaced, but will have 12 month follow up assessment. 
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Data 
management 
 
19 
 
Data collected on paper source data will be either entered onto the 
electronic database by the local site or sent to the coordinating centre 
for data entry. These data are subjected to range and consistency 
checks and any queries so identified are checked against the paper 
records or with the relevant participating centre.  There are standard 
existing procedures for checking discordant data on paper records 
with each of the participating centres if necessary.   
Statistical 
methods 
20a Analysis will be done by intention-to-treat. Baseline characteristics of 
participants in the control and intervention arms will be summarised. 
The primary outcome will be seizure count in the final two weeks of 
the intervention period and in the baseline assessment period. Data 
will be analysed using a Poisson mixed model to account for 
clustering by centre (synonymous with therapist).  The randomised 
allocation will be entered into the model as a fixed effect as will an 
indicator of time point (baseline or end of study), whilst the centre will 
be included as a random effect. Analysis of secondary outcomes 
(those seizure free and responders) will be analysed using random 
effects logistic models - centre being the random effects and 
randomised group a fixed effect.  The process outcomes relating to 
tolerability and medium chain fatty acids in the KD group will be 
analysed using random effects modelling.  Therapist effects will be 
investigated further in supportive analyses.   
 
 
Methods: Monitoring 
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Data monitoring 21a The Committee will be made up of the following: Independent clinician 
– chair, independent dietitian, independent statistician and study 
statistican.   
 
It is the only body involved in a trial that has access to the unblinded 
comparative data.  The role of its members is to monitor these data 
and make recommendations to the TSC on whether there any ethical 
or safety reasons why the trial should not continue.  The safety, rights 
and well-being of the trial participants are paramount.  The Data 
Monitoring Committee (DMC) considers the need for any interim 
analysis advising the TSC regarding the release of data and/or 
information.  The DMC may be asked by the TSC, Trial Sponsor or 
Trial Funder to consider data emerging from other related studies.  
Membership of the DMC should be completely independent, small (3 
– 4 members) and comprise experts in the field, such as a clinician 
with experience in the relevant area and an expert trial statistician. 
Responsibility for calling and organising DMC meetings lies with the 
Chief Investigator, in association with the Chair of the DMC. The 
project team should provide the DMC with a comprehensive report, 
the content of which should be agreed in advance by the Chair of the 
DMC.  The DMC should meet at least annually, or more often as 
appropriate, and meetings should be timed so that reports can be fed 
into the TSC. 
 21b Analysis will be done on an intention-to-treat model. A full statistical 
analysis plan will be created by PRIMENT CTU, UCL.  The pilot study 
will run in two centres in London; Great Ormond Street Hospital for 
Children and the Evelina Children’s Hospital in London over the initial 
12 months.  Baseline characteristics of participants in the control and 
intervention arms will be summarised. Frequencies and measures of 
central tendency will be calculated by randomised group to check for 
differences in the data.   
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Harms 22 All adverse events will be recorded in the medical records and CRF 
following randomisation, apart from parent reported seizures which 
will be recorded in the seizure diary. Ongoing seizures are an 
expected adverse event in this population and only seizures that meet 
the seriousness criteria will be entered on the CRF AE,  The AE log 
will be reviewed at the TMG meetings although immediate review 
(within 24 hours) of SAEs will be performed by the CI/PI.  If the 
investigator suspects that the subjects’ condition has progressed 
faster due to the administration of the IMP, then they will record and 
report this as an unexpected adverse event.  Clinically significant 
abnormalities in the results of objective tests (e.g. laboratory 
variables, EEG) will also be recorded as adverse events. If the results 
are not expected as part of disease or IMP, these will also be 
recorded as unexpected.  All adverse events will be recorded with 
clinical symptoms and accompanied with a simple, brief description of 
the event, including dates as appropriate. 
Auditing 23 All Consent forms to be 100% checked and source data verification 
for at least 25% of the total patient numbers to be completed by the 
Trial Manager/Site Monitor.  Consistency between centres will be 
ensured by utilisation of a dietetic assistant who will visit each centre 
on two occasions during the course of the study to verify standard 
implementation of the diet and AED use as per the treatment manual 
written at the outset of the study. 
Ethics and dissemination 
Research ethics 
approval 
24 Favourable ethical opinion was obtained from NRES Committee 
London - Fulham (REC reference 14/LO/1230) on the 2nd September 
2014 and local R & D approval issued by Great Ormond Street 
Hospital for Children NHS Foundation Trust, Guy's and St Thomas' 
NHS Foundation Trust (to cover the Evelina London Children’s 
Hospital) and Cambridge University Hospitals NHS Foundation Trust.  
HRA approval was issued on the 18th May 2016 to cover local 
approval within the following centres: University Hospitals Bristol NHS 
Foundation Trust, Birmingham Children's Hospital NHS Foundation 
Trust, Alder Hey Children's Hospital, Leeds Teaching Hospitals NHS 
Trust, St George's University Hospitals NHS Foundation Trust and 
Central Manchester University Hospitals Foundation Trust.  
Confirmation of Capacity and Capability were also carried out by the 
above centres and an “open to recruitment” letter issued by the 
sponsor, University College London (UCL).     
Protocol 
amendments 
25 The protocol and all agreed substantial protocol amendments, will be 
documented and submitted for ethical and regulatory approval prior to 
implementation.  It is the responsibility of the Chief Investigator/ 
Principal Investigator or designee at each site to ensure that all 
subsequent amendments gain the necessary approval. 
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Consent or assent 26a Eligible children will be consented via their parents. 
 26b All data will be handled in accordance with the UK Data Protection Act 
1998.  The Case Report Forms (CRFs) will not bear the subject’s 
name or other personal identifiable data.  The subject’s initials, date of 
birth and trial identification number, will be used for identification. 
Confidentiality 27 All paper source data are kept in a secure area at the coordinating 
centre during the course of the study and then stored by the chief 
investigator for 20 years.   
 
Declaration of 
interests 
28 JHC and SH have submitted a patent for C10, with UCL Business and 
Vitaflo, in the treatment of epilepsy.  JHCy; JHC has received royalties 
for a chapter on childhood epilepsy in Brain Diseases of the Nervous 
System, and as editor of Paediatric Epilepsy; has received research 
support from the National Institute for Health and Research, the 
European Framework FP7, the Charles Wolfson Foundation, Action 
Medical Research (AMR), SPARKS and Vitaflo, is Chief Investigator 
(UK) for studies funded by GW Pharma, and has received honoraria 
paid to her department for participation in advisory boards from 
Zogenix, GW Pharma, Eisai, Sanofi and Nutricia.  JHC is also an 
NIHR Senior Investigator for Paediatrics.  SH has received grant 
funding from Vitaflo and acts as a consultant.  STJ, NS, CE, RW, KV, 
HM, NF, RK, LM, TM, IN, EN, AL, AP, SA and PF have no competing 
interests.   
Access to data 29 The investigator(s)/ institution(s) will permit trial-related monitoring, 
audits, REC review, and regulatory inspection(s), providing direct 
access to source data/documents.  Trial participants are informed of 
this during the informed consent discussion.  Participants will consent 
to provide access to their medical notes.   
Ancillary and 
post-trial care 
30 Participants may also be able to claim compensation for injury caused 
by participation in this clinical trial without the need to prove 
negligence on the part of University College London or another party. 
Participants who sustain injury and wish to make a claim for 
compensation should do so in writing in the first instance to the Chief 
Investigator, who will pass the claim to the Sponsor’s Insurers, via the 
Sponsor’s office. 
Dissemination 
policy 
31a Professor Nicholas Freemantle is the trial statistician who will be 
responsible for all statistical aspects of the trial from design through to 
analysis and dissemination.  All proposed publications will be 
discussed with Sponsor prior to publishing other than those presented 
at scientific forums/meetings. 
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*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 
Explanation & Elaboration for important clarification on the items. Amendments to the 
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT 
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” 
license. 
 
 
 
 31b STJ is the Trial Manager and PhD student on the trial.  JHC is the 
Prince of Wales’s Chair of Childhood Epilepsy, and Deputy Lead of 
the Developmental Neurosciences Programme at UCL-Institute of 
Child Health. 
 
Appendices   
Informed consent 
materials 
32 1: Informed consent form v1.0 dated 17/06/2014         
2: Patient information sheet v2.0 dated 02/09/2015 
3: GP letter v1.0 dated 17/06/2014 
                                        
Biological 
specimens 
33 The blood and urine samples for the secondary outcome will be 
processed at Local Labs. The blood samples to evaluate the plasma 
profiles of medium chain fatty acids and for the assessment of 
mitochondrial function (respiratory chain enzymes) and enrichment 
(citrate synthase) will be processed at the Chemical Pathology 
Laboratory at GOSH. 
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Figure 1: The schedule of enrolment interventions and assessments 
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Allowed deviation window N/A +/-2 days  +/-2 days +/- 1 week 
Informed Consent  X 
 
       
Assessment of Eligibility Criteria X 
 
X       
Review of Medical History X 
 
       
Review of Concomitant 
Medications  
 X 
X 
X X X X X X 
Assessment of Adverse Events   X X X X X X X 
Trial Intervention – ketogenic diet 
** 
 X 
X 
X X 
  
  
Physical 
Exam 
Complete 
1
  X        X 
Symptom-Directed  X (X) (X) (X) (X) (X) (X) (X) 
Vital Signs  (X) (X) (X) (X) (X) (X) (X) (X) 
Clinical 
Laboratory
2
 
Haematology  X   X  X  X 
Biochemistry  X   X  X  X 
Urinalysis  X   X  X  X 
Home 
monitoring 
** 
Urine dipstick + 
Blood spot 
ketones 
3
 
  X** X** X**     
Special 
Assay or 
Procedure
4
 
Fatty acids (blood 
sample to Simon 
Heales at ICH)** 
  X**  X**     
Comparator group (Further AED 
treatment relevant to trial) 
 
 
X X X    
 
Quality of Life (ITQOL-97)  X   X    X 
Seizure Diary Data  
(to be entered in eCRFs through 
discussion with patient and 
review of their seizure diary) 
 X X X X X X X X 
Neuropsychological Assessment 
(Vineland) 
 X       X 
KD Side effects questionnaire**  
 
 X** X** X** X** X** X** 
KD Food diary  X        
*At baseline, all procedures should be done before randomisation 
**Ketogenic diet group only 
 (X) – As indicated/appropriate 
1
 Complete physical includes weight, length, head circumference, general examination 
2
Tests to be done: Haematology – Full Blood Count (FBC) ; Biochemistry – liver function tests, renal function tests, calcium, urate, glucose, 
phosphate, vitamin D, selenium, zinc, cholesterol, carnitine profile and  beta-hydroxybutyrate; Urinalysis – organic acids, urine calcium and 
creatinine ratio. Results must be received prior to randomisation.   
3
 Home monitoring urine dipstick and blood spot ketones done twice a day and recorded in Seizure diary (only KD arm) 
4
Special assay or procedure – Blood sample to be analysed by Simon Heales at ICH. 
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Appendix 1: Informed consent form v1.0 dated 17/06/2014         
 
 
PARENTAL CONSENT FORM 
 
Study Protocol Number: 13/0656 
 
Patient Identification Number for this trial: …………………… 
 
Title of project: Ketogenic diet in infants with epilepsy (KIWE) 
 
Centre Name: ………………………………… 
Please initial box  
 
1. I confirm that I have read and understand the information sheet 
dated............................. (version............) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these answered 
satisfactorily.  
 
2. I understand that my child’s participation is voluntary and that we are free to 
withdraw at any time without giving any reason, without his/her medical care or legal 
rights being affected.  
 
3. I understand that relevant sections of my child’s medical notes and data collected 
during the study, may be looked at by individuals from the sponsor of the trial 
(University College London) and responsible persons authorised by the sponsor, from 
regulatory authorities or from the NHS Trust, where it is relevant to my child taking 
part in this research. I give permission for these individuals to have access to my 
child’s records.  
 
4. I agree to my child’s GP being informed of his/her participation in the study.  
 
 
5. I agree for …………………………………………to take part in the above study.  
 
 
 
            
  
Name of parent & relationship           Date               Signature  
with the trial subject 
 
 
            
  
Name of Person              Date               Signature  
taking consent (delegated by PI) 
 
 
 
When completed: 1 for participant; 1 (original) for researcher site file; 1 to be kept in medical 
notes. 
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Appendix 2: Patient information sheet v2.0 dated 02/09/2015 
 
 
INFORMATION SHEET FOR PARENTS/GUARDIANS 
 
Study Title: Ketogenic Diet in Infants With Epilepsy (KIWE) 
  
We would like to invite you and your child to take part in our research study.  Before you 
decide we would like you to understand why the research is being done and what it would 
involve for you.  One of our team will go through the information sheet with you and answer 
any questions you may have. 
 
 Please take time to read the following information carefully and ask questions if anything is 
not clear, or if you would like further information. Take time to decide whether or not you 
wish for your child to take part. 
 
Part 1 tells you the purpose of this study and what will happen to your child if you take part.  
Part 2 gives you more detailed information about the conduct of the study.   
 
PART 1 
 
1. What is the purpose of the study? 
We aim to find out the effectiveness of the ketogenic diet (KD) in reducing seizures, 
compared to the use of further medicines that  are used to help seizures (anti-epileptic drugs 
or AEDs) in children aged 3 months to 2 years, who have failed to respond to two or more 
AEDs.  
 
The ketogenic diet has been shown to be successful in controlling seizures in many 
observational studies, and in a randomised trial in older children (aged 2 to 16 years). We 
wish to determine if this is the case in younger children. 
 
The ketogenic diet is a low carbohydrate and high fat diet designed to mimic the effects of 
starvation on the body. It is carefully planned to provide sufficient energy and protein to 
maintain growth and development. The basis of the diet is that the main energy source is fat, 
which is used in the body and produces molecules called ketones.  
 
 We will also examine the possible role of a component of the diet, medium chain fatty acids, 
in giving the antiepileptic effect.  The study would be the first of its kind in children under two 
years of age, and would make a significant contribution to the evidence-base for treatment of 
infants with epilepsy. 
 
2. Why has my child been invited? 
Your child has been invited to take part in this study because they have ongoing epileptic 
seizures despite treatment with 2 or more antiepileptic drugs.  We aim to include 160 
children across the UK to take part in this study. 
 
3. Does my child have to take part? 
No. The decision for you and your child to take part in the study is entirely voluntary and you 
may refuse to take part without giving a reason. We will describe the study and go through 
this information sheet. If you agree to take part, we will then ask you to sign a consent form. 
You are free to withdraw at any time without giving a reason. This would not affect the 
standard of care your child receives.  
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4. What will happen to my child if they take part? 
If your child is eligible to enter the study, he/she will be assigned randomly to one of two 
groups. This is a randomised trial as sometimes we don‘t know which way of treating 
patients is best. To find out, we need to compare different treatments. We put people into 
groups and give each group a different treatment. The results are compared to see if one is 
better. To try to make sure the groups are the same to start with, each patient is put into a 
group by chance (randomly).    
 
One group will receive a further antiepileptic drug treatment as per routine practice and the 
other group will follow the ketogenic diet for 8 weeks.  
 
We put each patient into a group randomly because we want to prevent selection bias by 
using the play of chance to assign participants. This means that the decision on which group 
your child is assigned to will not be related to their diagnosis or responsiveness to treatment, 
but to chance. As one group will receive intervention (ketogenic diet) calculated by a 
dietician, to ensure fair statistical comparison with a group with no dietician, slightly more 
children will be randomised to receive the diet (92) than a further AED (68). If your child is 
randomised to receive a further AED and their seizures continue, you will be offered the 
possibility of initiating the ketogenic diet after the 8-week period if their seizures are no 
better. 
 
Whichever group your child is in, they will be in the study for a total of 12 months. There will 
be a maximum of 9 study visits: screening, baseline and randomisation, at 4 weeks, 8 weeks 
and at 3, 6, 9, and 12 months. Most of the assessments and procedures are carried out as 
routine care; however, a few extra assessments as part of the research study will be 
undertaken. Please note that not all procedures will be carried out at all study visits and that 
a couple of extra visits may be required. After 8 weeks if your child has received a further 
AED and seizures continue, you will be offered the possibility of initiating the ketogenic diet.  
Please see the flow chart on page 8, which shows a summary of the study. 
 
Assessments 
 Physical examination: children in both groups will have a full examination to check 
their physical condition including weight, length, head circumference, blood pressure, 
pulse, and temperature. Also you will be asked to provide information about your 
child’s general health, medical history and the medications they take. 
 
 Blood tests: children in both groups will also have a blood test to ensure that 
mineral and supplement levels are appropriate and to make sure that their liver, 
kidneys and blood lipid levels are normal. These will be re-checked at 8 weeks, and 
should your child be on a ketogenic diet 6 monthly thereafter. 
 
Assessments as part of this study 
 Dietitian visit and training: parents will be asked to complete a 3 day food diary 
based on which the dietitian will calculate your child’s ketogenic diet. Training will be 
given so that the diet can be followed at home as per standard practice in your 
hospital. 
 
 Ketogenic diet: children in the ketogenic diet group will be asked to follow the 
prescribed ketogenic diet for 8 weeks. During that period their ketone levels should 
be monitored twice daily and recorded in the seizure diary. 
 
 Questionnaires: during study visits you will be asked to complete questionnaires to 
describe how your child is feeling. 
 
 Seizure diary: you will be asked to complete a seizure diary for your child daily 
between visits. 
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 Blood samples: to evaluate chemicals in the blood and assess whether medium 
chain fatty acids are associated with seizure control. This is only for patients on the 
ketogenic diet. 
 
 Adverse events: the study team will ask you about any side effects or problems your 
child is experiencing.  
 
 Home monitoring: During the ketogenic diet the level of ketones in your child’s urine 
(dipstick) or blood (finger prick) should be tested and recorded, twice daily. We will 
provide home monitoring kits and training on how to use these kits.  
 
The assessments are shown in a table on page 9 of the information sheet. 
 
If randomised to receive the ketogenic diet a dietitian will provide constant advice and 
guidance. The ketogenic diet can be demanding and restrictive in order to provide the 
desired results, as you will need to follow specific meal plans desiged for your child, aiming 
to finish the prescribed intake of food. Prior to the start you will have to complete a food diary 
for 3 days (including 1 weekend day). Based on the information provided the dietitian will 
calculate the diet to suit your child’s needs and will provide instructions regarding meal 
planning and allowed/prohibited foods.  
 
The ketogenic diet will be the classical version which is calculated in a ratio of ketone-
producing foods (fat) to those which reduce ketone production (carbohydrate and protein). 
Foods appropriate to the age of your child will be included, however carbohydrate-rich foods 
are not allowed, such as bread, pasta, breakfast cereals, sweets and some fruits and 
vegetables like bananas and potatoes. Typical foods included in the diet are meat, fish, eggs 
and cheese (protein sources), low-carbohydrate fruit and vegetables such as dark-leafy 
greens, berry fruits and avocados, and a fat source at each meal, for example, cream, butter 
or oil. A prepared ketogenic formula feed called Ketocal will usually be included in the diet; 
this is available on prescription. If your child is still being breast fed, feeding can be 
continued on the ketogenic diet, in combination with the ketogenic feed which will be given in 
a prescribed amount before each breastfeed. If breast milk is expressed, this can be mixed 
with the ketogenic feed to the correct ketogenic ratio. Infants on a ketogenic diet can be 
weaned as normal; the dietitian will give advice on how to adapt standard weaning foods to 
the correct ketogenic ratio by adding extra fat. 
 
Training about carrying out the diet at home will be provided. The diet should be followed for 
8 weeks, after which a decision will be made in consultation with your neurologist and 
dietitian if your child should continue on the diet, if it is proving effective for seizure control. 
During the diet the level of ketones in your child’s urine (dipstick) or blood (finger prick) 
should be tested and recorded, twice daily. After 8 weeks if your child does not improve on 
the ketogenic diet, your doctor will change back to standard medical practice (AEDs). 
 
If randomised to the anti-epileptic drug group, your child will receive the further anti-epileptic 
medicines as decided by your doctor. After 8 weeks if your child has received a further AED 
and seizures continue, you will be offered the possibility of initiating the ketogenic diet. 
 
 
5. What are the alternatives for diagnosis or treatment?  
Your child has not responded to at least 2 antiepileptic drugs. Both a further antiepileptic 
drug treatment and the ketogenic diet that are part of this study are commonly provided in 
your hospital as standard treatment for children with complex epilepsy.  
 
If your child takes part in the study, treatment with the usual medication will continue. Your 
child’s doctor will remain free to give alternative treatment to that specified in the study, at 
any stage if it is deemed to be in the best interest of your child. 
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If your child is not eligible to take part in the study or you decide not to participate or to 
withdraw, the treatment to be received will be discussed with the child’s doctor and will 
depend upon the policy of your child’s hospital. 
 
6. What are the possible disadvantages and risks of taking part?  
Before you decide for your child to take part in the study we would like to inform you of all 
possible risks of taking part so you can make a fully informed decision: 
 
 A finger-prick test used to check for the presence of ketones in blood may cause 
temporary pain and soreness. 
 When blood samples are taken your child might experience some temporary 
discomfort and bruising at the site of needle entry may occur. If required, anaesthetic 
cream before sample collection will be used. 
 Possible side effects of the ketogenic diet are explained below 
 
Before deciding to take part, you should also consider if taking part in the study will affect 
any private medical insurance you have and seek advice from your insurance company if 
necessary. 
 
7. What are the side effects of any treatment received when taking part?  
The change to a new diet as well as the restrictive nature on the ketogenic diet can cause a 
number of side effects, which can usually be minimised by making minor adjustments to the 
diet. 
 
From previous research we have found the following effects: 
 
Common side effects may include: lethargy (initial stage) and acidosis, constipation, 
change in lipid (fat) levels in the blood, diarrhoea, hunger, vomiting, increase in blood uric 
acid levels. 
 
Occasional side effects may include: renal stones, hypoglycaemia. 
 
Rare side effects may include: pancreatitis, bruising, vitamin and/or mineral deficiency, 
abdominal pain, gallstone formation, dehydration. 
 
We will monitor for possible side effects during the study by asking you to complete a 
ketogenic diet side effects questionnaire at the start of the diet, and at 4 and 8 weeks 
afterwards. We will also give you training and look at the results of the home monitoring 
urine and blood finger prick tests to check for abnormal blood and urine levels. Your child will 
be clinically monitored for side effects at each clinic visit and regular blood samples will help 
us to check the presence of unwanted side effects. 
 
8. What are the possible benefits of taking part?  
The ketogenic diet is known to reduce the frequency of seizures in children with drug 
resistant epilepsy; however, there is no guarantee that being in the study will help your child. 
Ultimately, results of this study may help to optimise future standard treatment in children 
with drug resistant epilepsy. 
 
9. What happens when the research study stops?  
The study stops when all the children have completed their interventions and follow-up visits 
or if the study has to be closed prematurely for any other reason. Your child’s doctor will 
arrange for their care to continue as per standard practice. Your hospital offers antiepileptic 
drug therapy and ketogenic diet services as standard treatment for complex paediatric 
epilepsy; therefore, those services will also be available after the end of the study after a 
consultation with your child’s doctor. 
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10. What if there is a problem?  
Any complaint about the way you have been dealt with during the clinical trial or any possible 
harm you might suffer will be addressed. The detailed information concerning this is given in 
Part 2 of this information sheet. If you have any concerns or complaints you should contact 
your study doctor in the first instance. 
 
11. Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2.  
 
12. Expenses and payments  
Participation in the study is voluntary and no payment is to be received. The follow-up and 
study visits will be planned to coincide with routine care visits, therefore, no additional travel 
expenses are expected. In the case that you and your child are required to attend extra 
study visits reasonable travel expenses will be reimbursed upon production of valid receipts 
(i.e. petrol, train tickets). 
 
13. Contact Details 
 
Further details: Please contact your doctor or another study team member on the 
telephone number given below if you have any queries about the study or you would like to 
discuss your child’s participation in the study. Should your child have to visit another doctor 
tell him/ her that they are taking part in this study so that he/ she can contact your study 
doctor if necessary. 
 
Local Investigator: xxxxxxxxxxxxxxxxxxxxxxxx 
Local Dietitian: xxxxxxxxxxxxxxxxxxxxxxxx 
This completes Part 1 of the Information Sheet. 
 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision.  
 
 
PART 2 
 
14. What if relevant new information becomes available?  
Sometimes we get new information about the treatment being studied.  If this happens, your 
research doctor will tell you about it and discuss with you whether you want to continue in 
the study. If you decide to withdraw your research doctor will make arrangements for the 
care of your child to continue. If you decide to continue in the study you will be asked to sign 
an updated consent form. Also, on receiving new information your research doctor might 
consider it to be in your best interests to withdraw your child from the study treatment. He / 
she will explain the reasons and arrange for your care to continue. 
 
If the study is stopped for any other reason, we will tell you why and arrange your continuing 
care.  
 
15. What will happen if I don’t want to carry on with the study?  
You can withdraw your child from the study at any time but we advise you to keep in contact 
with us to let us know your progress. Information collected up to that point will still be used. 
Any stored blood or tissue samples that can still be identified as yours will be destroyed if 
you wish.  
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16. What if there is a problem?  
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions  
 
 If you remain unhappy and wish to complain formally, you can do this by contacting your 
local NHS Patient Advice and Liaison Service, known as PALS.   
 
Every care will be taken in the course of this clinical trial.  However in the unlikely event that 
you are injured by taking part, compensation may be available.  
 
If you suspect that the injury is the result of the Sponsor’s (University College London) or the 
hospital's negligence then you may be able to claim compensation.  After discussing with 
your study doctor, please make the claim in writing to Professor Helen Cross who is the 
Chief Investigator for the clinical trial and is based at the Neurosciences Unit, UCL Institute 
of Child Health, 4/5 Long Yard, London WC1N 3LU; telephone number: 0207 5994105; fax 
number: 0207 430 0032; email address: h.cross@ucl.ac.uk. The Chief Investigator will then 
pass the claim to the Sponsor’s Insurers, via the Sponsor’s office. You may have to bear the 
costs of the legal action initially, and you should consult a lawyer about this. 
 
Participants may also be able to claim compensation for injury caused by participation in this 
clinical trial without the need to prove negligence on the part of University College London 
(UCL) or another party. You should discuss this possibility with your study doctor in the 
same way as above.  
 
Regardless of this, if you wish to complain, or have any concerns about any aspect of the 
way you have been approached or treated by members of staff or about any side effects 
(adverse events) you may have experienced due to your participation in the clinical trial, the 
normal National Health Service complaints mechanisms are available to you. Please ask 
your study doctor if you would like more information on this. Details can also be obtained 
from the Department of Health website: http://www.dh.gov.uk. 
 
 
17. Will my taking part in this study be kept confidential?  
If you consent to your child taking part in this study, the records obtained while your child is 
in this study as well as related health records will remain strictly confidential at all times. The 
information will be held securely on paper and electronically at your treating hospital and at 
UCL-Institute of Child Health, the main site managing this research under the provisions of 
the 1998 Data Protection Act. Your child’s name and personal details will not be passed to 
anyone else outside the research team or the Sponsor (UCL). Your child will be allocated a 
trial number, which will be used as a code to identify you on all trial forms.  Any information 
about your child which leaves the hospital will have their name, address and any personal 
data removed so that you cannot be recognised (if it is applicable to your research). 
 
Your records will be available to people authorised to work on the trial but may also need to 
be made available to people authorised by the Sponsor, which is the organisation 
responsible for ensuring that the study is carried out correctly.  By signing the consent form 
you agree to this access for the current study and any further research that may be 
conducted in relation to it, even if you withdraw from the current study.  
 
The information collected about you may also be shown to authorised people from the UK 
Regulatory Authority (the Medicines and Healthcare Products Regulatory Authority); this is to 
ensure that the study is carried out to the highest possible scientific standards.  All will have 
a duty of confidentiality to you as a research participant. 
 
If you withdraw consent from further study treatment, unless you object, your data and 
samples will remain on file and will be included in the final study analysis. 
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In line with the regulations, at the end of the study your data will be securely archived for a 
minimum of 20 years. Arrangements for confidential destruction will then be made.  
 
18. Will my GP be informed of my involvement?  
With your permission, your GP will be notified that you and your child are taking part in this 
study. 
No information will be released without your consent. 
 
19. What will happen to any samples I give?  
Your child’s blood sample will be analysed by the Clinician Scientist based at UCL - Institute 
of Child Health, who is part of the research team.  All information collected including seizure 
data, ketone levels and neurodevelopmental evaluation will be held on a computer server at 
UCL and only Professor Cross and the research team undertaking this study will have 
access to it.  At the end of the study the samples will be stored for 20 years maintaining 
confidentiality to uphold good research practice. All samples given to us will be considered a 
gift. We will only use these samples for this study and they will be stored and disposed of 
securely.  
 
20. What will happen to the results of the research study?  
The results of the study will be available after it finishes and will be published in a medical 
journal as well as presented at scientific conferences. The data will be anonymous and none 
of the patients involved in the trial will be identified in any report or publication.  
 
Should you wish to see the results, or the publication, please ask your study doctor.  
 
21. Who is organising and funding the research?  
The research is being organised through UCL-Institute of Child Health in collaboration with 
Great Ormond Street Hospital for Children NHS Trust, Evelina Children’s Hospital, Alder Hey 
Children’s Hospital, Royal Manchester Children’s Hospital, Addenbrookes NHS Trust, 
Birmingham Children’s Hospital, Leeds Teaching Hospital NHS Trust, University of Bristol, 
Matthew’s Friends Clinics and Young Epilepsy. It is funded by the National Institute for 
Health Research and sponsored by UCL.  
 
 
22. Who has reviewed the study?  
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect you and your child’s interests.  This study has been reviewed 
and given favourable opinion by London Fulham Research Ethics Committee.  
 
23. Further information and contact details  
You are encouraged to ask any questions you wish, before, during or after your treatment. If 
you have any questions about the study, please speak to your study nurse or doctor, who 
will be able to provide you with up to date information about the procedure(s) involved. If you 
wish to read the research on which this study is based, please ask your study nurse or 
doctor. If you require any further information or have any concerns while taking part in the 
study please contact one of the following people: 
 
Local Investigator: xxxxxxxxxxxxxxxxxxxxxxx 
Local Dietitian: xxxxxxxxxxxxxxxxxxxxxxx 
 
Alternatively if you or your relatives would like general information about research please 
review the UKCRN website: www.UKCRN.org.uk  
 
If you decide you would like to take part then please read and sign the consent form. You will 
be given a copy of this information sheet and the consent form to keep. A copy of the 
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consent form will be filed in your patient notes, one will be filed with the study records and 
one may be sent to the Research Sponsor. 
 
You can have more time to think this over if you are at all unsure. 
 
 
Thank you for taking the time to read this information sheet and to consider this 
study. 
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Appendix 3: GP letter v1.0 dated 17/06/2014 
 
 
Department: 0207 188 3998 
Fax: 0207 188 4629  
Main Switchboard: 020 7188 7188 
 
Date: 
 
 
 
Dear Dr............. 
 
Re: Patient name....................................................................... 
 
Ketogenic diet treatment of epilepsy in infants 
 
The above-named patient from your practice has consented to enter the above study 
being carried out at xxxxxxxxxxxxxxxxxx in collaboration with UCL – Institute of Child 
Health. 
 
The parent/guardian has been given an information sheet (a copy of the 
parent/guardian information leaflet is attached) and is aware that he/she/their child 
can withdraw from the study at any time without giving a reason. 
 
Follow-up will be organised by the research team and should not entail any 
additional workload for you. 
 
Please do not hesitate to contact me if you require any further details about this 
study. 
 
With best wishes 
 
 
<Local PI contact>    Professor Helen Cross 
      Prince of Wales’s Chair of Childhood 
Department       UCL-Institute of Child Health 
      4/5 Long Yard 
      London 
      Telephone number: 0207 5994107 
      Email:h.cross@ucl.ac.uk 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional file 2 - Schematic of Trial Design
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Additional file 3. Treatment Side Effects Questionnaire
Study Protocol Number: 13/0656
Patient Identification Number for this trial: ……………………
Patient Initials: ………………….
Centre Name: …………………………………
TREATMENT SIDE EFFECTS QUESTIONNAIRE
Have you noticed any of the following side effects in your child during the past 4
weeks / 3 months / 6 months? (please circle)
a = yes, it is a very serious problem
b = yes, it is a moderately serious problem
c = yes, it is a mild problem
d = no or not applicable
1 drowsiness, sleepiness a b c d
2 sickness a b c d
3 constipation a b c d
4 diarrhoea a b c d
5 abdominal pain a b c d
6 loss of appetite a b c d
7 lack of energy a b c d
8 hyperactivity a b c d
9 hunger a b c d
10 decreased concentration a b c d
11 behavioural disturbance a b c d
……………………………….. …………….…………….
Signature Date

Additional file 4. (AED consensus flowchart)
Carbamazepine (Tegratol)
Clobazam (Frisium)
Clonazepam (Rivotril)
Ethosuximide (Zarontin)
Lacosmide (Vimpat)
Lamotrigine (Lamictal)
Levetiracetam (Keppra)
Nitrazepam (Mogadon)
Phenytoin (Epanutin)
Rufinamide (Inovelon)
Sodium Valproate (Epilim)
Stiripentol (Diacomit)
Topiramate (Topamax)
Vigabatrin (Sabril)
Zonisamide (Zonegran)
Onset of epilepsy <24m
Spasms: assume had VGB/steroidsNot spasms
LEV, TPM, VPA, NTZ
Dravet:
Assume
PA, CLB, STP
Not Dravet:
Select on main
seizure type
TPM
Absence:
Assume
VPA/LEV
Generalised Focal: assume CBZ /LEV
GTC/tonic:
Assume
VPA/LEV
TPM
ETX TPM

Additional file 5. Names and descriptions of investigational medicinal products
used in KIWE
Medicines Formulation Concentration
Carbamazepine (Tegratol) Liquid 100mg/5mL
Clobazam (Frisium)
Oral suspension 5mg/5mL
10mg/5mL
Clonazepam (Rivotril)
Oral solution 0.5mg/5mL2mg/5mL
Oral drops 2.5mg/mL
Ethosuximide (Zarontin) Syrup 250mg/5mL
Lacosmide (Vimpat) Syrup 10mg/mL
Lamotrigine (Lamictal) Dispersible tablets
2mg
5mg
25mg
100mg
Levetiracetam (Keppra) Oral solution 100mg/mL
Nitrazepam (Mogadon)
Oral suspension 2.5mg/5mL
Phenytoin (Epanutin)
Suspension 30mg/5mL
Infatabs 50mg
Capsules 25, 50, 100mg
Rufinamide (Inovelon) Oral suspension 40mg/mL
Sodium Valproate (Epilim) Oral solution 200mg/5mL
Stiripentol (Diacomit) Powder (sachets)
250mg
500mg
Topiramate (Topamax)
Sprinkle capsules
15mg
25mg
50mg
Vigabatrin (Sabril) Powder (Sachets) 500mg
Zonisamide (Zonegran) Capsules
25mg
50mg
100mg
